Global (United States, European Union and China) MRSA Antibiotics research
Global (United States, European Union and China) MRSA Antibiotics research

MRSA Antibiotics Comprehensive Study by Type (Vancomycin, Teicoplanin, Linezolid, Cubicin, Others), Route of Administration (Oral, Parenteral), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), End User (Adults, Children) Players and Region - Global Market Outlook to 2024

MRSA Antibiotics Market Segmented into XX Submarkets. | Forecast Years: 2019- 2024  

Nov 2019 Edition 211 Pages 211 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Industry Background:
MRSA (Methicillin-Resistant Staphylococcus Aureus), is a form of contagious bacterial infection which is resistant to various antibiotics which includes methicillin, amoxicillin, penicillin, and oxacillin. This resistance makes it stimulating to treat. A methicillin is an antibiotic-associated to penicillin; it was once effective against staphylococci (staph), a kind of bacteria. Staph bacteria have since developed a resistance to penicillin-related antibiotics, which includes methicillin, these resistant bacteria are called methicillin-resistant Staphylococcus aureus, or MRSA.This growth is primarily driven by Stringent Government Regulations and Initiatives to Improve Antibiotic Innovation.

Globally, a noticeable market trend is evident Increased Funding For Antibiotic Research. Major Players, such as Basilea Pharmaceutica Ltd. (Switzerland), The Medicines Company (United States), Theravance Biopharma (Cayman Islands), Allergan (Ireland), Merck & Co., Inc. (United States), Pfizer, Inc. (United States), Roche Holding AG (Switzerland) and Novartis (Switzerland) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

Market Drivers
  • Stringent Government Regulations
  • Initiatives to Improve Antibiotic Innovation

Market Trend
  • Increased Funding For Antibiotic Research

Restraints
  • A dearth of Systematic Surveillance for MRSA Infection in Developing Countries

Opportunities
High Potential Growth Offered By Developing Region
Challenges
Development of Drug-Resistant Strains

AdvanceMarketAnalytics follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.

Customization of the Report:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Type
  • Vancomycin
  • Teicoplanin
  • Linezolid
  • Cubicin
  • Others
By Route of Administration
  • Oral
  • Parenteral

By Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By End User
  • Adults
  • Children

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Stringent Government Regulations
      • 3.2.2. Initiatives to Improve Antibiotic Innovation
    • 3.3. Market Challenges
      • 3.3.1. Development of Drug-Resistant Strains
    • 3.4. Market Trends
      • 3.4.1. Increased Funding For Antibiotic Research
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global MRSA Antibiotics, by Type, Route of Administration, Distribution Channel, End User and Region (value and price ) (2013-2018)
    • 5.1. Introduction
    • 5.2. Global MRSA Antibiotics (Value)
      • 5.2.1. Global MRSA Antibiotics by: Type (Value)
        • 5.2.1.1. Vancomycin
        • 5.2.1.2. Teicoplanin
        • 5.2.1.3. Linezolid
        • 5.2.1.4. Cubicin
        • 5.2.1.5. Others
      • 5.2.2. Global MRSA Antibiotics by: Route of Administration (Value)
        • 5.2.2.1. Oral
        • 5.2.2.2. Parenteral
      • 5.2.3. Global MRSA Antibiotics by: Distribution Channel (Value)
        • 5.2.3.1. Hospital Pharmacy
        • 5.2.3.2. Retail Pharmacy
        • 5.2.3.3. Online Pharmacy
      • 5.2.4. Global MRSA Antibiotics by: End User (Value)
        • 5.2.4.1. Adults
        • 5.2.4.2. Children
      • 5.2.5. Global MRSA Antibiotics Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global MRSA Antibiotics (Price)
      • 5.3.1. Global MRSA Antibiotics by: Type (Price)
  • 6. MRSA Antibiotics: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2018)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Basilea Pharmaceutica Ltd. (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. The Medicines Company (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Theravance Biopharma (Cayman Islands)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Allergan (Ireland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Merck & Co., Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Pfizer, Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Roche Holding AG (Switzerland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Novartis (Switzerland)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
  • 7. Global MRSA Antibiotics Sale, by Type, Route of Administration, Distribution Channel, End User and Region (value and price ) (2019-2024)
    • 7.1. Introduction
    • 7.2. Global MRSA Antibiotics (Value)
      • 7.2.1. Global MRSA Antibiotics by: Type (Value)
        • 7.2.1.1. Vancomycin
        • 7.2.1.2. Teicoplanin
        • 7.2.1.3. Linezolid
        • 7.2.1.4. Cubicin
        • 7.2.1.5. Others
      • 7.2.2. Global MRSA Antibiotics by: Route of Administration (Value)
        • 7.2.2.1. Oral
        • 7.2.2.2. Parenteral
      • 7.2.3. Global MRSA Antibiotics by: Distribution Channel (Value)
        • 7.2.3.1. Hospital Pharmacy
        • 7.2.3.2. Retail Pharmacy
        • 7.2.3.3. Online Pharmacy
      • 7.2.4. Global MRSA Antibiotics by: End User (Value)
        • 7.2.4.1. Adults
        • 7.2.4.2. Children
      • 7.2.5. Global MRSA Antibiotics Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global MRSA Antibiotics (Price)
      • 7.3.1. Global MRSA Antibiotics by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. MRSA Antibiotics: by Type(USD Million)
  • Table 2. MRSA Antibiotics Vancomycin , by Region USD Million (2013-2018)
  • Table 3. MRSA Antibiotics Teicoplanin , by Region USD Million (2013-2018)
  • Table 4. MRSA Antibiotics Linezolid , by Region USD Million (2013-2018)
  • Table 5. MRSA Antibiotics Cubicin , by Region USD Million (2013-2018)
  • Table 6. MRSA Antibiotics Others , by Region USD Million (2013-2018)
  • Table 7. MRSA Antibiotics: by Route of Administration(USD Million)
  • Table 8. MRSA Antibiotics Oral , by Region USD Million (2013-2018)
  • Table 9. MRSA Antibiotics Parenteral , by Region USD Million (2013-2018)
  • Table 10. MRSA Antibiotics: by Distribution Channel(USD Million)
  • Table 11. MRSA Antibiotics Hospital Pharmacy , by Region USD Million (2013-2018)
  • Table 12. MRSA Antibiotics Retail Pharmacy , by Region USD Million (2013-2018)
  • Table 13. MRSA Antibiotics Online Pharmacy , by Region USD Million (2013-2018)
  • Table 14. MRSA Antibiotics: by End User(USD Million)
  • Table 15. MRSA Antibiotics Adults , by Region USD Million (2013-2018)
  • Table 16. MRSA Antibiotics Children , by Region USD Million (2013-2018)
  • Table 17. South America MRSA Antibiotics, by Country USD Million (2013-2018)
  • Table 18. South America MRSA Antibiotics, by Type USD Million (2013-2018)
  • Table 19. South America MRSA Antibiotics, by Route of Administration USD Million (2013-2018)
  • Table 20. South America MRSA Antibiotics, by Distribution Channel USD Million (2013-2018)
  • Table 21. South America MRSA Antibiotics, by End User USD Million (2013-2018)
  • Table 22. Brazil MRSA Antibiotics, by Type USD Million (2013-2018)
  • Table 23. Brazil MRSA Antibiotics, by Route of Administration USD Million (2013-2018)
  • Table 24. Brazil MRSA Antibiotics, by Distribution Channel USD Million (2013-2018)
  • Table 25. Brazil MRSA Antibiotics, by End User USD Million (2013-2018)
  • Table 26. Argentina MRSA Antibiotics, by Type USD Million (2013-2018)
  • Table 27. Argentina MRSA Antibiotics, by Route of Administration USD Million (2013-2018)
  • Table 28. Argentina MRSA Antibiotics, by Distribution Channel USD Million (2013-2018)
  • Table 29. Argentina MRSA Antibiotics, by End User USD Million (2013-2018)
  • Table 30. Rest of South America MRSA Antibiotics, by Type USD Million (2013-2018)
  • Table 31. Rest of South America MRSA Antibiotics, by Route of Administration USD Million (2013-2018)
  • Table 32. Rest of South America MRSA Antibiotics, by Distribution Channel USD Million (2013-2018)
  • Table 33. Rest of South America MRSA Antibiotics, by End User USD Million (2013-2018)
  • Table 34. Asia Pacific MRSA Antibiotics, by Country USD Million (2013-2018)
  • Table 35. Asia Pacific MRSA Antibiotics, by Type USD Million (2013-2018)
  • Table 36. Asia Pacific MRSA Antibiotics, by Route of Administration USD Million (2013-2018)
  • Table 37. Asia Pacific MRSA Antibiotics, by Distribution Channel USD Million (2013-2018)
  • Table 38. Asia Pacific MRSA Antibiotics, by End User USD Million (2013-2018)
  • Table 39. China MRSA Antibiotics, by Type USD Million (2013-2018)
  • Table 40. China MRSA Antibiotics, by Route of Administration USD Million (2013-2018)
  • Table 41. China MRSA Antibiotics, by Distribution Channel USD Million (2013-2018)
  • Table 42. China MRSA Antibiotics, by End User USD Million (2013-2018)
  • Table 43. Japan MRSA Antibiotics, by Type USD Million (2013-2018)
  • Table 44. Japan MRSA Antibiotics, by Route of Administration USD Million (2013-2018)
  • Table 45. Japan MRSA Antibiotics, by Distribution Channel USD Million (2013-2018)
  • Table 46. Japan MRSA Antibiotics, by End User USD Million (2013-2018)
  • Table 47. India MRSA Antibiotics, by Type USD Million (2013-2018)
  • Table 48. India MRSA Antibiotics, by Route of Administration USD Million (2013-2018)
  • Table 49. India MRSA Antibiotics, by Distribution Channel USD Million (2013-2018)
  • Table 50. India MRSA Antibiotics, by End User USD Million (2013-2018)
  • Table 51. South Korea MRSA Antibiotics, by Type USD Million (2013-2018)
  • Table 52. South Korea MRSA Antibiotics, by Route of Administration USD Million (2013-2018)
  • Table 53. South Korea MRSA Antibiotics, by Distribution Channel USD Million (2013-2018)
  • Table 54. South Korea MRSA Antibiotics, by End User USD Million (2013-2018)
  • Table 55. Taiwan MRSA Antibiotics, by Type USD Million (2013-2018)
  • Table 56. Taiwan MRSA Antibiotics, by Route of Administration USD Million (2013-2018)
  • Table 57. Taiwan MRSA Antibiotics, by Distribution Channel USD Million (2013-2018)
  • Table 58. Taiwan MRSA Antibiotics, by End User USD Million (2013-2018)
  • Table 59. Australia MRSA Antibiotics, by Type USD Million (2013-2018)
  • Table 60. Australia MRSA Antibiotics, by Route of Administration USD Million (2013-2018)
  • Table 61. Australia MRSA Antibiotics, by Distribution Channel USD Million (2013-2018)
  • Table 62. Australia MRSA Antibiotics, by End User USD Million (2013-2018)
  • Table 63. Rest of Asia-Pacific MRSA Antibiotics, by Type USD Million (2013-2018)
  • Table 64. Rest of Asia-Pacific MRSA Antibiotics, by Route of Administration USD Million (2013-2018)
  • Table 65. Rest of Asia-Pacific MRSA Antibiotics, by Distribution Channel USD Million (2013-2018)
  • Table 66. Rest of Asia-Pacific MRSA Antibiotics, by End User USD Million (2013-2018)
  • Table 67. Europe MRSA Antibiotics, by Country USD Million (2013-2018)
  • Table 68. Europe MRSA Antibiotics, by Type USD Million (2013-2018)
  • Table 69. Europe MRSA Antibiotics, by Route of Administration USD Million (2013-2018)
  • Table 70. Europe MRSA Antibiotics, by Distribution Channel USD Million (2013-2018)
  • Table 71. Europe MRSA Antibiotics, by End User USD Million (2013-2018)
  • Table 72. Germany MRSA Antibiotics, by Type USD Million (2013-2018)
  • Table 73. Germany MRSA Antibiotics, by Route of Administration USD Million (2013-2018)
  • Table 74. Germany MRSA Antibiotics, by Distribution Channel USD Million (2013-2018)
  • Table 75. Germany MRSA Antibiotics, by End User USD Million (2013-2018)
  • Table 76. France MRSA Antibiotics, by Type USD Million (2013-2018)
  • Table 77. France MRSA Antibiotics, by Route of Administration USD Million (2013-2018)
  • Table 78. France MRSA Antibiotics, by Distribution Channel USD Million (2013-2018)
  • Table 79. France MRSA Antibiotics, by End User USD Million (2013-2018)
  • Table 80. Italy MRSA Antibiotics, by Type USD Million (2013-2018)
  • Table 81. Italy MRSA Antibiotics, by Route of Administration USD Million (2013-2018)
  • Table 82. Italy MRSA Antibiotics, by Distribution Channel USD Million (2013-2018)
  • Table 83. Italy MRSA Antibiotics, by End User USD Million (2013-2018)
  • Table 84. United Kingdom MRSA Antibiotics, by Type USD Million (2013-2018)
  • Table 85. United Kingdom MRSA Antibiotics, by Route of Administration USD Million (2013-2018)
  • Table 86. United Kingdom MRSA Antibiotics, by Distribution Channel USD Million (2013-2018)
  • Table 87. United Kingdom MRSA Antibiotics, by End User USD Million (2013-2018)
  • Table 88. Netherlands MRSA Antibiotics, by Type USD Million (2013-2018)
  • Table 89. Netherlands MRSA Antibiotics, by Route of Administration USD Million (2013-2018)
  • Table 90. Netherlands MRSA Antibiotics, by Distribution Channel USD Million (2013-2018)
  • Table 91. Netherlands MRSA Antibiotics, by End User USD Million (2013-2018)
  • Table 92. Rest of Europe MRSA Antibiotics, by Type USD Million (2013-2018)
  • Table 93. Rest of Europe MRSA Antibiotics, by Route of Administration USD Million (2013-2018)
  • Table 94. Rest of Europe MRSA Antibiotics, by Distribution Channel USD Million (2013-2018)
  • Table 95. Rest of Europe MRSA Antibiotics, by End User USD Million (2013-2018)
  • Table 96. MEA MRSA Antibiotics, by Country USD Million (2013-2018)
  • Table 97. MEA MRSA Antibiotics, by Type USD Million (2013-2018)
  • Table 98. MEA MRSA Antibiotics, by Route of Administration USD Million (2013-2018)
  • Table 99. MEA MRSA Antibiotics, by Distribution Channel USD Million (2013-2018)
  • Table 100. MEA MRSA Antibiotics, by End User USD Million (2013-2018)
  • Table 101. Middle East MRSA Antibiotics, by Type USD Million (2013-2018)
  • Table 102. Middle East MRSA Antibiotics, by Route of Administration USD Million (2013-2018)
  • Table 103. Middle East MRSA Antibiotics, by Distribution Channel USD Million (2013-2018)
  • Table 104. Middle East MRSA Antibiotics, by End User USD Million (2013-2018)
  • Table 105. Africa MRSA Antibiotics, by Type USD Million (2013-2018)
  • Table 106. Africa MRSA Antibiotics, by Route of Administration USD Million (2013-2018)
  • Table 107. Africa MRSA Antibiotics, by Distribution Channel USD Million (2013-2018)
  • Table 108. Africa MRSA Antibiotics, by End User USD Million (2013-2018)
  • Table 109. North America MRSA Antibiotics, by Country USD Million (2013-2018)
  • Table 110. North America MRSA Antibiotics, by Type USD Million (2013-2018)
  • Table 111. North America MRSA Antibiotics, by Route of Administration USD Million (2013-2018)
  • Table 112. North America MRSA Antibiotics, by Distribution Channel USD Million (2013-2018)
  • Table 113. North America MRSA Antibiotics, by End User USD Million (2013-2018)
  • Table 114. United States MRSA Antibiotics, by Type USD Million (2013-2018)
  • Table 115. United States MRSA Antibiotics, by Route of Administration USD Million (2013-2018)
  • Table 116. United States MRSA Antibiotics, by Distribution Channel USD Million (2013-2018)
  • Table 117. United States MRSA Antibiotics, by End User USD Million (2013-2018)
  • Table 118. Canada MRSA Antibiotics, by Type USD Million (2013-2018)
  • Table 119. Canada MRSA Antibiotics, by Route of Administration USD Million (2013-2018)
  • Table 120. Canada MRSA Antibiotics, by Distribution Channel USD Million (2013-2018)
  • Table 121. Canada MRSA Antibiotics, by End User USD Million (2013-2018)
  • Table 122. Mexico MRSA Antibiotics, by Type USD Million (2013-2018)
  • Table 123. Mexico MRSA Antibiotics, by Route of Administration USD Million (2013-2018)
  • Table 124. Mexico MRSA Antibiotics, by Distribution Channel USD Million (2013-2018)
  • Table 125. Mexico MRSA Antibiotics, by End User USD Million (2013-2018)
  • Table 126. MRSA Antibiotics: by Type(USD/Units)
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. MRSA Antibiotics: by Type(USD Million)
  • Table 136. MRSA Antibiotics Vancomycin , by Region USD Million (2019-2024)
  • Table 137. MRSA Antibiotics Teicoplanin , by Region USD Million (2019-2024)
  • Table 138. MRSA Antibiotics Linezolid , by Region USD Million (2019-2024)
  • Table 139. MRSA Antibiotics Cubicin , by Region USD Million (2019-2024)
  • Table 140. MRSA Antibiotics Others , by Region USD Million (2019-2024)
  • Table 141. MRSA Antibiotics: by Route of Administration(USD Million)
  • Table 142. MRSA Antibiotics Oral , by Region USD Million (2019-2024)
  • Table 143. MRSA Antibiotics Parenteral , by Region USD Million (2019-2024)
  • Table 144. MRSA Antibiotics: by Distribution Channel(USD Million)
  • Table 145. MRSA Antibiotics Hospital Pharmacy , by Region USD Million (2019-2024)
  • Table 146. MRSA Antibiotics Retail Pharmacy , by Region USD Million (2019-2024)
  • Table 147. MRSA Antibiotics Online Pharmacy , by Region USD Million (2019-2024)
  • Table 148. MRSA Antibiotics: by End User(USD Million)
  • Table 149. MRSA Antibiotics Adults , by Region USD Million (2019-2024)
  • Table 150. MRSA Antibiotics Children , by Region USD Million (2019-2024)
  • Table 151. South America MRSA Antibiotics, by Country USD Million (2019-2024)
  • Table 152. South America MRSA Antibiotics, by Type USD Million (2019-2024)
  • Table 153. South America MRSA Antibiotics, by Route of Administration USD Million (2019-2024)
  • Table 154. South America MRSA Antibiotics, by Distribution Channel USD Million (2019-2024)
  • Table 155. South America MRSA Antibiotics, by End User USD Million (2019-2024)
  • Table 156. Brazil MRSA Antibiotics, by Type USD Million (2019-2024)
  • Table 157. Brazil MRSA Antibiotics, by Route of Administration USD Million (2019-2024)
  • Table 158. Brazil MRSA Antibiotics, by Distribution Channel USD Million (2019-2024)
  • Table 159. Brazil MRSA Antibiotics, by End User USD Million (2019-2024)
  • Table 160. Argentina MRSA Antibiotics, by Type USD Million (2019-2024)
  • Table 161. Argentina MRSA Antibiotics, by Route of Administration USD Million (2019-2024)
  • Table 162. Argentina MRSA Antibiotics, by Distribution Channel USD Million (2019-2024)
  • Table 163. Argentina MRSA Antibiotics, by End User USD Million (2019-2024)
  • Table 164. Rest of South America MRSA Antibiotics, by Type USD Million (2019-2024)
  • Table 165. Rest of South America MRSA Antibiotics, by Route of Administration USD Million (2019-2024)
  • Table 166. Rest of South America MRSA Antibiotics, by Distribution Channel USD Million (2019-2024)
  • Table 167. Rest of South America MRSA Antibiotics, by End User USD Million (2019-2024)
  • Table 168. Asia Pacific MRSA Antibiotics, by Country USD Million (2019-2024)
  • Table 169. Asia Pacific MRSA Antibiotics, by Type USD Million (2019-2024)
  • Table 170. Asia Pacific MRSA Antibiotics, by Route of Administration USD Million (2019-2024)
  • Table 171. Asia Pacific MRSA Antibiotics, by Distribution Channel USD Million (2019-2024)
  • Table 172. Asia Pacific MRSA Antibiotics, by End User USD Million (2019-2024)
  • Table 173. China MRSA Antibiotics, by Type USD Million (2019-2024)
  • Table 174. China MRSA Antibiotics, by Route of Administration USD Million (2019-2024)
  • Table 175. China MRSA Antibiotics, by Distribution Channel USD Million (2019-2024)
  • Table 176. China MRSA Antibiotics, by End User USD Million (2019-2024)
  • Table 177. Japan MRSA Antibiotics, by Type USD Million (2019-2024)
  • Table 178. Japan MRSA Antibiotics, by Route of Administration USD Million (2019-2024)
  • Table 179. Japan MRSA Antibiotics, by Distribution Channel USD Million (2019-2024)
  • Table 180. Japan MRSA Antibiotics, by End User USD Million (2019-2024)
  • Table 181. India MRSA Antibiotics, by Type USD Million (2019-2024)
  • Table 182. India MRSA Antibiotics, by Route of Administration USD Million (2019-2024)
  • Table 183. India MRSA Antibiotics, by Distribution Channel USD Million (2019-2024)
  • Table 184. India MRSA Antibiotics, by End User USD Million (2019-2024)
  • Table 185. South Korea MRSA Antibiotics, by Type USD Million (2019-2024)
  • Table 186. South Korea MRSA Antibiotics, by Route of Administration USD Million (2019-2024)
  • Table 187. South Korea MRSA Antibiotics, by Distribution Channel USD Million (2019-2024)
  • Table 188. South Korea MRSA Antibiotics, by End User USD Million (2019-2024)
  • Table 189. Taiwan MRSA Antibiotics, by Type USD Million (2019-2024)
  • Table 190. Taiwan MRSA Antibiotics, by Route of Administration USD Million (2019-2024)
  • Table 191. Taiwan MRSA Antibiotics, by Distribution Channel USD Million (2019-2024)
  • Table 192. Taiwan MRSA Antibiotics, by End User USD Million (2019-2024)
  • Table 193. Australia MRSA Antibiotics, by Type USD Million (2019-2024)
  • Table 194. Australia MRSA Antibiotics, by Route of Administration USD Million (2019-2024)
  • Table 195. Australia MRSA Antibiotics, by Distribution Channel USD Million (2019-2024)
  • Table 196. Australia MRSA Antibiotics, by End User USD Million (2019-2024)
  • Table 197. Rest of Asia-Pacific MRSA Antibiotics, by Type USD Million (2019-2024)
  • Table 198. Rest of Asia-Pacific MRSA Antibiotics, by Route of Administration USD Million (2019-2024)
  • Table 199. Rest of Asia-Pacific MRSA Antibiotics, by Distribution Channel USD Million (2019-2024)
  • Table 200. Rest of Asia-Pacific MRSA Antibiotics, by End User USD Million (2019-2024)
  • Table 201. Europe MRSA Antibiotics, by Country USD Million (2019-2024)
  • Table 202. Europe MRSA Antibiotics, by Type USD Million (2019-2024)
  • Table 203. Europe MRSA Antibiotics, by Route of Administration USD Million (2019-2024)
  • Table 204. Europe MRSA Antibiotics, by Distribution Channel USD Million (2019-2024)
  • Table 205. Europe MRSA Antibiotics, by End User USD Million (2019-2024)
  • Table 206. Germany MRSA Antibiotics, by Type USD Million (2019-2024)
  • Table 207. Germany MRSA Antibiotics, by Route of Administration USD Million (2019-2024)
  • Table 208. Germany MRSA Antibiotics, by Distribution Channel USD Million (2019-2024)
  • Table 209. Germany MRSA Antibiotics, by End User USD Million (2019-2024)
  • Table 210. France MRSA Antibiotics, by Type USD Million (2019-2024)
  • Table 211. France MRSA Antibiotics, by Route of Administration USD Million (2019-2024)
  • Table 212. France MRSA Antibiotics, by Distribution Channel USD Million (2019-2024)
  • Table 213. France MRSA Antibiotics, by End User USD Million (2019-2024)
  • Table 214. Italy MRSA Antibiotics, by Type USD Million (2019-2024)
  • Table 215. Italy MRSA Antibiotics, by Route of Administration USD Million (2019-2024)
  • Table 216. Italy MRSA Antibiotics, by Distribution Channel USD Million (2019-2024)
  • Table 217. Italy MRSA Antibiotics, by End User USD Million (2019-2024)
  • Table 218. United Kingdom MRSA Antibiotics, by Type USD Million (2019-2024)
  • Table 219. United Kingdom MRSA Antibiotics, by Route of Administration USD Million (2019-2024)
  • Table 220. United Kingdom MRSA Antibiotics, by Distribution Channel USD Million (2019-2024)
  • Table 221. United Kingdom MRSA Antibiotics, by End User USD Million (2019-2024)
  • Table 222. Netherlands MRSA Antibiotics, by Type USD Million (2019-2024)
  • Table 223. Netherlands MRSA Antibiotics, by Route of Administration USD Million (2019-2024)
  • Table 224. Netherlands MRSA Antibiotics, by Distribution Channel USD Million (2019-2024)
  • Table 225. Netherlands MRSA Antibiotics, by End User USD Million (2019-2024)
  • Table 226. Rest of Europe MRSA Antibiotics, by Type USD Million (2019-2024)
  • Table 227. Rest of Europe MRSA Antibiotics, by Route of Administration USD Million (2019-2024)
  • Table 228. Rest of Europe MRSA Antibiotics, by Distribution Channel USD Million (2019-2024)
  • Table 229. Rest of Europe MRSA Antibiotics, by End User USD Million (2019-2024)
  • Table 230. MEA MRSA Antibiotics, by Country USD Million (2019-2024)
  • Table 231. MEA MRSA Antibiotics, by Type USD Million (2019-2024)
  • Table 232. MEA MRSA Antibiotics, by Route of Administration USD Million (2019-2024)
  • Table 233. MEA MRSA Antibiotics, by Distribution Channel USD Million (2019-2024)
  • Table 234. MEA MRSA Antibiotics, by End User USD Million (2019-2024)
  • Table 235. Middle East MRSA Antibiotics, by Type USD Million (2019-2024)
  • Table 236. Middle East MRSA Antibiotics, by Route of Administration USD Million (2019-2024)
  • Table 237. Middle East MRSA Antibiotics, by Distribution Channel USD Million (2019-2024)
  • Table 238. Middle East MRSA Antibiotics, by End User USD Million (2019-2024)
  • Table 239. Africa MRSA Antibiotics, by Type USD Million (2019-2024)
  • Table 240. Africa MRSA Antibiotics, by Route of Administration USD Million (2019-2024)
  • Table 241. Africa MRSA Antibiotics, by Distribution Channel USD Million (2019-2024)
  • Table 242. Africa MRSA Antibiotics, by End User USD Million (2019-2024)
  • Table 243. North America MRSA Antibiotics, by Country USD Million (2019-2024)
  • Table 244. North America MRSA Antibiotics, by Type USD Million (2019-2024)
  • Table 245. North America MRSA Antibiotics, by Route of Administration USD Million (2019-2024)
  • Table 246. North America MRSA Antibiotics, by Distribution Channel USD Million (2019-2024)
  • Table 247. North America MRSA Antibiotics, by End User USD Million (2019-2024)
  • Table 248. United States MRSA Antibiotics, by Type USD Million (2019-2024)
  • Table 249. United States MRSA Antibiotics, by Route of Administration USD Million (2019-2024)
  • Table 250. United States MRSA Antibiotics, by Distribution Channel USD Million (2019-2024)
  • Table 251. United States MRSA Antibiotics, by End User USD Million (2019-2024)
  • Table 252. Canada MRSA Antibiotics, by Type USD Million (2019-2024)
  • Table 253. Canada MRSA Antibiotics, by Route of Administration USD Million (2019-2024)
  • Table 254. Canada MRSA Antibiotics, by Distribution Channel USD Million (2019-2024)
  • Table 255. Canada MRSA Antibiotics, by End User USD Million (2019-2024)
  • Table 256. Mexico MRSA Antibiotics, by Type USD Million (2019-2024)
  • Table 257. Mexico MRSA Antibiotics, by Route of Administration USD Million (2019-2024)
  • Table 258. Mexico MRSA Antibiotics, by Distribution Channel USD Million (2019-2024)
  • Table 259. Mexico MRSA Antibiotics, by End User USD Million (2019-2024)
  • Table 260. MRSA Antibiotics: by Type(USD/Units)
  • Table 261. Research Programs/Design for This Report
  • Table 262. Key Data Information from Secondary Sources
  • Table 263. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global MRSA Antibiotics: by Type USD Million (2013-2018)
  • Figure 5. Global MRSA Antibiotics: by Route of Administration USD Million (2013-2018)
  • Figure 6. Global MRSA Antibiotics: by Distribution Channel USD Million (2013-2018)
  • Figure 7. Global MRSA Antibiotics: by End User USD Million (2013-2018)
  • Figure 8. South America MRSA Antibiotics Share (%), by Country
  • Figure 9. Asia Pacific MRSA Antibiotics Share (%), by Country
  • Figure 10. Europe MRSA Antibiotics Share (%), by Country
  • Figure 11. MEA MRSA Antibiotics Share (%), by Country
  • Figure 12. North America MRSA Antibiotics Share (%), by Country
  • Figure 13. Global MRSA Antibiotics: by Type USD/Units (2013-2018)
  • Figure 14. Global MRSA Antibiotics share by Players 2018 (%)
  • Figure 15. Global MRSA Antibiotics share by Players (Top 3) 2018(%)
  • Figure 16. Global MRSA Antibiotics share by Players (Top 5) 2018(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. Basilea Pharmaceutica Ltd. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 19. Basilea Pharmaceutica Ltd. (Switzerland) Revenue: by Geography 2018
  • Figure 20. The Medicines Company (United States) Revenue, Net Income and Gross profit
  • Figure 21. The Medicines Company (United States) Revenue: by Geography 2018
  • Figure 22. Theravance Biopharma (Cayman Islands) Revenue, Net Income and Gross profit
  • Figure 23. Theravance Biopharma (Cayman Islands) Revenue: by Geography 2018
  • Figure 24. Allergan (Ireland) Revenue, Net Income and Gross profit
  • Figure 25. Allergan (Ireland) Revenue: by Geography 2018
  • Figure 26. Merck & Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 27. Merck & Co., Inc. (United States) Revenue: by Geography 2018
  • Figure 28. Pfizer, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 29. Pfizer, Inc. (United States) Revenue: by Geography 2018
  • Figure 30. Roche Holding AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 31. Roche Holding AG (Switzerland) Revenue: by Geography 2018
  • Figure 32. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 33. Novartis (Switzerland) Revenue: by Geography 2018
  • Figure 34. Global MRSA Antibiotics: by Type USD Million (2019-2024)
  • Figure 35. Global MRSA Antibiotics: by Route of Administration USD Million (2019-2024)
  • Figure 36. Global MRSA Antibiotics: by Distribution Channel USD Million (2019-2024)
  • Figure 37. Global MRSA Antibiotics: by End User USD Million (2019-2024)
  • Figure 38. South America MRSA Antibiotics Share (%), by Country
  • Figure 39. Asia Pacific MRSA Antibiotics Share (%), by Country
  • Figure 40. Europe MRSA Antibiotics Share (%), by Country
  • Figure 41. MEA MRSA Antibiotics Share (%), by Country
  • Figure 42. North America MRSA Antibiotics Share (%), by Country
  • Figure 43. Global MRSA Antibiotics: by Type USD/Units (2019-2024)
Some of the key companies/manufacturers profiled in the report
  • Basilea Pharmaceutica Ltd. (Switzerland)
  • The Medicines Company (United States)
  • Theravance Biopharma (Cayman Islands)
  • Allergan (Ireland)
  • Merck & Co., Inc. (United States)
  • Pfizer, Inc. (United States)
  • Roche Holding AG (Switzerland)
  • Novartis (Switzerland)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation